Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn’s Disease
Ben Kang, So Yoon Choi, Young Ok Choi, et al.
Journal of Crohn s and Colitis (2018) Vol. 13, Iss. 2, pp. 189-197
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Challenges in IBD Research 2024: Precision Medicine
Sana Syed, Brigid S. Boland, Lauren T Bourke, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. Supplement_2, pp. S39-S54
Open Access | Times Cited: 9
Therapeutic drug monitoring in inflammatory bowel disease
Konstantinos Papamichael, Adam S. Cheifetz
Current Opinion in Gastroenterology (2019) Vol. 35, Iss. 4, pp. 302-310
Open Access | Times Cited: 56
Maintenance‐phase serum anti‐TNF levels are not associated with mucosal healing in pediatric Crohn's disease
Rinat Grabovski, Shirley Regev, Manar Matar, et al.
Journal of Pediatric Gastroenterology and Nutrition (2025)
Closed Access
Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease
John L. Lyles, Aditi Mulgund, Laura Bauman, et al.
Inflammatory Bowel Diseases (2020) Vol. 27, Iss. 4, pp. 482-492
Open Access | Times Cited: 45
A novel clinical radiomics nomogram at baseline to predict mucosal healing in Crohn’s disease patients treated with infliximab
Chao Zhu, Jing Hu, Xia Wang, et al.
European Radiology (2022) Vol. 32, Iss. 10, pp. 6628-6636
Closed Access | Times Cited: 21
Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology
Konstantinos Papamichael, Adam S. Cheifetz
Current Opinion in Rheumatology (2020) Vol. 32, Iss. 4, pp. 371-379
Open Access | Times Cited: 27
CTE-Based Radiomics Models Can Identify Mucosal Healing in Patients with Crohn's Disease
Chang Rong, Chao Zhu, Li He, et al.
Academic Radiology (2023) Vol. 30, pp. S199-S206
Closed Access | Times Cited: 8
Evaluation of Mucosal Healing in Crohn’s Disease: Radiomics Models of Intestinal Wall and Mesenteric Fat Based on Dual-Energy CT
Chao Zhu, Chang Rong, Jian Song, et al.
Deleted Journal (2024) Vol. 37, Iss. 2, pp. 715-724
Open Access | Times Cited: 2
Clinical utility of C‐reactive protein‐to‐albumin ratio in the management of patients with inflammatory bowel disease
Anke L. Nguyen, Claudia Brick, David Liu, et al.
JGH Open (2024) Vol. 8, Iss. 4
Open Access | Times Cited: 2
Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease
Raffaella Franca, Debora Curci, Marianna Lucafò, et al.
Expert Opinion on Drug Metabolism & Toxicology (2019) Vol. 15, Iss. 7, pp. 527-539
Open Access | Times Cited: 23
Korean Children and Adolescents with Crohn's Disease Are More Likely to Present with Perianal Fistulizing Disease at Diagnosis Compared to Their European Counterparts
Ben Kang, Jung Eun Kim, Jae Hun Jung, et al.
Pediatric Gastroenterology Hepatology & Nutrition (2020) Vol. 23, Iss. 1, pp. 49-49
Open Access | Times Cited: 23
Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies
Eric Cheah, James Guoxian Huang
World Journal of Gastroenterology (2023) Vol. 29, Iss. 10, pp. 1539-1550
Open Access | Times Cited: 6
Therapeutic Drug Monitoring of Biologics in Crohn’s Disease
Laurie B. Grossberg, Adam S. Cheifetz, Konstantinos Papamichael
Gastroenterology Clinics of North America (2022) Vol. 51, Iss. 2, pp. 299-317
Closed Access | Times Cited: 10
Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients
So Yoon Choi, Young Ok Choi, Yon Ho Choe, et al.
Journal of Korean Medical Science (2020) Vol. 35, Iss. 17
Open Access | Times Cited: 14
Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease
Eun Sil Kim, Sujin Choi, Byung‐Ho Choe, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease
Eun Sil Kim, Ben Kang
World Journal of Gastroenterology (2023) Vol. 29, Iss. 18, pp. 2784-2797
Open Access | Times Cited: 4
Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
So Yoon Choi, Yiyoung Kwon, Sujin Choi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
Nanja Bevers, Ron J. Keizer, Dennis R. Wong, et al.
Clinical Pharmacokinetics (2024) Vol. 63, Iss. 4, pp. 529-538
Open Access | Times Cited: 1
Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress
Debora Curci, Marianna Lucafò, Giuliana Decorti, et al.
Expert Opinion on Biological Therapy (2024)
Closed Access | Times Cited: 1
Infliximab Trough Levels Are Associated With Transmural Sonographic Healing in Inflammatory Bowel Disease
Rose Vaughan, Elise Murphy, Michelle Nalder, et al.
Inflammatory Bowel Diseases (2022) Vol. 29, Iss. 7, pp. 1080-1088
Closed Access | Times Cited: 7
Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study
Ryan S. Funk, Valentina Shakhnovich, Yu Kyoung Cho, et al.
Pediatric Rheumatology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 10
The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn’s disease
Yue Zhang, Wenyu Jiang, Chenjing Xu, et al.
Scandinavian Journal of Gastroenterology (2023) Vol. 59, Iss. 3, pp. 269-279
Closed Access | Times Cited: 3
A population physiologically‐based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab
Hsuan‐Ping Chang, Valentina Shakhnovich, Adam Frymoyer, et al.
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 1, pp. 290-302
Open Access | Times Cited: 8
Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease
Eran Zittan, A. Hillary Steinhart, Pavel Goldstein, et al.
Clinical and Translational Gastroenterology (2021) Vol. 12, Iss. 10, pp. e00401-e00401
Open Access | Times Cited: 7
Therapeutic Drug Monitoring Increases Drug Retention of Anti–Tumor Necrosis Factor Alpha Agents in Pediatric Patients With Crohn’s Disease
Yoel Gofin, Manar Matar, Raanan Shamir, et al.
Inflammatory Bowel Diseases (2019)
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top